Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$2,427 Mln
P/E Ratio
100.45
P/B Ratio
2.06
Industry P/E
--
Debt to Equity
0.04
ROE
0.02 %
ROCE
2.11 %
Div. Yield
0 %
Book Value
14.72
EPS
0.3
CFO
$-112.82 Mln
EBITDA
$-225.21 Mln
Net Profit
$-387.29 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Veracyte (VCYT)
| -22.73 | -3.89 | -24.59 | 57.33 | 9.89 | 5.62 | 13.77 |
|
BSE Sensex*
| 1.74 | 3.51 | 4.97 | 8.92 | 11.19 | 21.04 | 11.14 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Veracyte (VCYT)
| 43.52 | 15.93 | -42.40 | -15.82 | 75.29 | 121.94 | 91.96 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 35.59 | 9,973.38 | 20.56 | 23.13 | |
| 288.99 | 8,956.07 | 23.48 | 58.42 | |
| 25.13 | 9,559.25 | -- | -28.77 | |
| 100.68 | 10,030.35 | 30.81 | 14.16 |
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis;... Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California. Address: 6000 Shoreline Court, South San Francisco, CA, United States, 94080 Read more
CEO & Director
Mr. Marc A. Stapley
CEO & Director
Mr. Marc A. Stapley
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Veracyte Inc (VCYT) stood at $ 1,300 Mln as on 31-Dec-24
The share price of Veracyte Inc (VCYT) is $30.60 (NASDAQ) as of 21-Apr-2025 16:00 EDT. Veracyte Inc (VCYT) has given a return of 9.89% in the last 3 years.
Veracyte Inc (VCYT) has a market capitalisation of $ 2,427 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of Veracyte Inc (VCYT) is 100.45 times as on 21-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Veracyte Inc (VCYT) and enter the required number of quantities and click on buy to purchase the shares of Veracyte Inc (VCYT).
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California. Address: 6000 Shoreline Court, South San Francisco, CA, United States, 94080
The CEO & director of Mr. Marc A. Stapley. is Veracyte Inc (VCYT), and CFO & Sr. VP is Mr. Marc A. Stapley.
There is no promoter pledging in Veracyte Inc (VCYT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Veracyte Inc. (VCYT) | Ratios |
|---|---|
|
Return on equity(%)
|
2.17
|
|
Operating margin(%)
|
5.78
|
|
Net Margin(%)
|
5.41
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Veracyte Inc (VCYT) was $0 Mln.
$-0.54
(
